Kim Yung Hui, Kang Yeon Soo, Lee Hyo Seok, Choi Won, You In Cheon, Yoon Kyung Chul
1 Department of Ophthalmology, Research Institute of Medical Sciences, Chonnam National University Medical School and Hospital , Gwangju, Korea.
2 Department of Ophthalmology, Chonbuk National University Medical School and Hospital , Jeonju, Korea.
J Ocul Pharmacol Ther. 2017 Oct;33(8):635-643. doi: 10.1089/jop.2017.0019. Epub 2017 Aug 28.
The aim of this study was to evaluate the effectiveness of combined tear film therapy targeted to aqueous, mucin, and lipid layers in patients with refractory evaporative dry eye (EDE) with short tear film breakup time (TBUT).
The patients who had EDE with short TBUT and severe symptoms refractory to artificial tears were treated with hyaluronic acid (HA) 0.15% and diquafosol tetrasodium (DQS) 3% (Group 1), HA and carbomer-based lipid-containing eyedrops (Liposic EDO Gel, LPO) (Group 2), or HA, DQS, and LPO (Group 3). Ocular Surface Disease Index (OSDI) score, visual analog scale (VAS) symptom score, TBUT, Schirmer score, and corneal and conjunctival staining scores were evaluated, and noninvasive tear film breakup time (NIBUT) and tear meniscus height were measured using Keratograph 5 M before and 1 and 3 months after treatment.
OSDI scores, VAS scores, TBUT, and NIBUT were improved at 1 and 3 months after treatment in all groups (all P < 0.05). At each follow-up visit, the total OSDI, OSDI symptom, and all VAS scores were significantly lower in group 3 compared with groups 1 and 2 (all P < 0.05). In addition, TBUT and NIBUT were significantly higher in group 3 compared with groups 1 and 2 (all P < 0.05). No significant adverse effects were noted in the groups during treatment.
Mucin or lipid-targeting agents combined with aqueous supplements in patients with refractory EDE with short TBUT might improve subjective symptoms and TBUT. Of this, targeting whole tear film layers was most effective in improving ocular symptoms and tear film quality.
本研究旨在评估针对水液层、黏蛋白层和脂质层的联合泪膜疗法对泪膜破裂时间(TBUT)短的难治性蒸发型干眼(EDE)患者的有效性。
对患有短TBUT且人工泪液治疗无效的重度症状的EDE患者,分别采用0.15%透明质酸(HA)和3%四水二喹富罗(DQS)治疗(第1组)、HA和含卡波姆的脂质眼药水(Liposic EDO Gel,LPO)治疗(第2组)或HA、DQS和LPO治疗(第3组)。评估眼表疾病指数(OSDI)评分、视觉模拟量表(VAS)症状评分、TBUT、泪液分泌试验评分以及角膜和结膜染色评分,并在治疗前、治疗后1个月和3个月使用角膜地形图仪5M测量无创泪膜破裂时间(NIBUT)和泪河高度。
所有组在治疗后1个月和3个月时OSDI评分、VAS评分、TBUT和NIBUT均有所改善(均P < 0.05)。在每次随访时,第3组的总OSDI、OSDI症状和所有VAS评分均显著低于第1组和第2组(均P < 0.05)。此外,第3组的TBUT和NIBUT显著高于第1组和第2组(均P < 0.05)。治疗期间各组均未观察到明显不良反应。
对于TBUT短的难治性EDE患者,黏蛋白或脂质靶向药物联合水液补充剂可能改善主观症状和TBUT。其中,针对整个泪膜层进行治疗在改善眼部症状和泪膜质量方面最有效。